Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship ...
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a patient-centric, commercial-stage biopharmaceutical company headquartered in Montréal, Québec, Canada. The company focuses on developing and, where possible, commercializing therapies for cardiovascular conditions that often present in episodic episodes. Its strategic emphasis is on creating medicines that can provide meaningful clinical relief for patients ...Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a patient-centric, commercial-stage biopharmaceutical company headquartered in Montréal, Québec, Canada. The company focuses on developing and, where possible, commercializing therapies for cardiovascular conditions that often present in episodic episodes. Its strategic emphasis is on creating medicines that can provide meaningful clinical relief for patients experiencing arrhythmia-driven events.
The company’s flagship asset is etripamil, an innovative channel blocker being advanced through clinical development across multiple cardiac arrhythmia indications. According to the provided company description, etripamil is in advanced clinical development, including Phase III trials for paroxysmal supraventricular tachycardia (PSVT) in both the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. In addition to internal development, Milestone has pursued licensing and collaboration arrangements to advance and distribute etripamil for both preventative and therapeutic applications in humans.
From a business and execution perspective, Milestone operates with a relatively small workforce (about 38 full-time employees per the provided data). This scale is typical of early commercial-stage biopharma companies, where core functions often include clinical development, regulatory/medical affairs, business development, and commercial planning. The financial metrics in the provided dataset also reflect the realities of a development-focused biopharmaceutical model: profitability and cash-flow metrics can be volatile and frequently negative during clinical advancement, while balance-sheet capacity and working capital management become critical.
In terms of cost structure and resourcing, biopharma companies like Milestone generally incur substantial R&D and clinical trial costs, along with regulatory, manufacturing/scaling, and commercialization preparation expenses. The company’s expense profile is consistent with an organization investing heavily in research and development to progress late-stage cardiovascular programs.
Key leadership includes Joseph G. Oliveto (President & CEO), who has served in senior leadership roles since 2017, and the company’s founder-level strategic guidance has been associated with Philippe Douville, PhD. The “wish” or direction implied by the company’s positioning is to help patients “every beat of the way” by delivering safer, more effective cardiovascular therapies—particularly for patients affected by PSVT and related episodic conditions—while continuing to advance etripamil toward broader clinical and market impact.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$1.5M
—
+134.9%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-63.1M
-51.9%
-9.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+92.6%
—
+33.6%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-4041.7%
—
+54.1%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-4078.8%
—
+53.3%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-49.3M
-70.8%
-40.5%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-3191.7%
—
+40.2%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
139.8%
-66.5%
+104.4%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
8.01x
-12.0%
-11.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Greetings. Welcome to the Milestone Pharma 2Q '26 Earnings Conference Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to Michael Wood from LifeSci Advisors. Thank you, Michael. You may begin.
Michael Wood: Hello. Thank you, and good morning, everyone, and welcome to Milestone Pharmaceuticals Second Quarter 2026 Financial Results and Business Update Conference Call. Earlier this morning, the company issued a press release providing an overview of its financial results for the quarter ended June 30, 2026, and recent corporate highlights. The release can be accessed on the Investors & Media section of the company's website, milestonepharma.com. Before we begin, I would like to remind you that some of the information presented on this conference call contains forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause actual clinical programs, future results, progress, timing, performances or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties associated with Milestone's business and factors that could cause or contribute to such differences are described in details in the company's filings with the SEC, including in the Risk Factors section of the annual report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 20, 2026. Speaking on the call today will be Joseph Oliveto, President and Chief Executive Officer; Lorenz Muller, Chief Commercial Officer; and Amit Hasija, Chief Financial Officer and EVP of Corporate Development. In addition, Dr. David Bharucha, the company's Chief Medical Officer, will also be available during the Q&A session. I will now turn the call over to Joseph Oliveto. Please go ahead.
Joseph Oliveto: Thank you, Michael. Good morning, everyone, and thank you for joining us today to hear about our progress through the second quarter. Until this year, patients experiencing sudden attacks of paroxysmal supraventricular tachycardia, or PSVT, had no FDA-approved self-administered treatment available to them. Now a growing population of patients in the United States have CARDAMYST in their homes, in their workplaces, in their pockets or wherever it's convenient for them to have on hand to treat their PSVT. Today, we're excited to report on our first full financial quarter since our commercial launch in mid-February. We're seeing growing evidence that physicians, patients and payers recognize the value of CARDAMYST as a new treatment paradigm for PSVT. I'll start by taking you through total scripts, the number of unique prescribers and patients filling prescriptions. And we'll report these figures for the quarter, compare them to the prior quarter and add them for the first half results. Realize that the first quarter is a partial quarter and first half figures represent …
